| dc.contributor | 心理系 | - |
| dc.creator (作者) | Lin, Chih-Lin;Liu, CH;Wang, CC;Liang, CC;Su, TH;Liu, CJ;Kao, Jia-Horng | - |
| dc.creator (作者) | 林志陵 | - |
| dc.date (日期) | 2015-09 | - |
| dc.date.accessioned | 3-Dec-2015 18:00:10 (UTC+8) | - |
| dc.date.available | 3-Dec-2015 18:00:10 (UTC+8) | - |
| dc.date.issued (上傳時間) | 3-Dec-2015 18:00:10 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/79592 | - |
| dc.description.abstract (摘要) | Goals/background: Aspartate aminotransferase to platelet ratio index (APRI) and FIB-4 index are noninvasive biomarkers to evaluate hepatic fibrosis. However, their usefulness in chronic hepatitis B (CHB) patients remains unclear. Methods: A total of 631 CHB patients were enrolled and randomly divided into a training set (n=420) and a validation set (n=211). Areas under receiver operating characteristic (AUROC) curves for FIB-4 index and APRI were compared to evaluate their diagnostic values in identifying significant fibrosis and cirrhosis. Results: The AUROC of FIB-4 index for the diagnosis of significant fibrosis and cirrhosis in the entire cohort was higher than that of APRI (0.769 vs. 0.704, P=0.0003 and 0.869 vs. 0.706, P<0.0001). By using cutoff APRI of 0.38 and 4.04 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 67.7% and 76.8%. At cutoff FIB-4 index of 0.87 and 3.40 in the validation set, the diagnostic accuracy for absence of significant fibrosis and presence of cirrhosis was 69.2% and 84.4%. Compared with patients with concordance, patients with overestimated score by FIB-4 index had a significantly higher serum alanine aminotransferase (ALT) level (299±245 vs. 168±196 U/L, P=0.001) as well as a higher ratio of hepatitis flare (ALT>400 U/L) (25% vs. 7.9%, P=0.008). Conclusions: FIB-4 index proves to be more reliable than APRI in predicting significant fibrosis and cirrhosis in CHB patients. By using FIB-4 index, a substantial proportion of patients could be identified correctly as significant fibrosis and cirrhosis without further invasive liver biopsy. | - |
| dc.format.extent | 110 bytes | - |
| dc.format.mimetype | text/html | - |
| dc.relation (關聯) | Journal Of Clinical Gastroenterology, 49(8), 705-713 | - |
| dc.title (題名) | Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B | - |
| dc.type (資料類型) | article | - |
| dc.identifier.doi (DOI) | 10.1097/MCG.0000000000000250 | - |
| dc.doi.uri (DOI) | http://dx.doi.org/10.1097/MCG.0000000000000250 | - |
